

Research Symposium

USING SMALL MOLECULES TO IDENTIFY CRITICAL HOST-CELLULAR PATHWAYS FOR BRUCELLA INFECTION

Thomas Kim, BA¹, Erika Lisabeth, PhD, Richard Neubig, MD, PhD, Bill Hong, PhD, Thomas O' Halloran, PhD, Aretha Fiebig, PhD, Sean Crosson, PhD

¹ College of Osteopathic Medicine, Michigan State University

<https://doi.org/10.51894/001c.123036>

Spartan Medical Research Journal

Vol. 9, Issue 2, 2024

60

INTRODUCTION/BACKGROUND

Brucella spp., a widespread group of zoonotic intracellular pathogens, pose substantial health threats to both animals and humans worldwide. While it is well-established that nearly all *Brucella* species can infect and multiply within mammalian phagocytes, our understanding of the specific host factors and cellular processes that facilitate *Brucella* survival in the host cell remains incomplete. A critical knowledge gap lies in the identification of host cellular processes that support *Brucella* survival during infection.

OBJECTIVES/HYPOTHESIS

Through pharmacologic and molecular characterization of select host-dependent processes, we aim to expand our understanding of *Brucella*-phagocyte interactions and uncover potential novel targets for host-directed therapeutic strategies.

METHODS

In order to identify host-cellular processes that are critical for *Brucella* replication in host phagocytes, we used a small molecule screening approach. We screened compounds from FDA-approved small molecule libraries to leverage their known mechanisms of actions and thereby infer host cellular processes that may be critical for *Brucella* survival. In collaboration with the Michigan State University's Assay

Development & Drug Repurposing Core (ADDRC), we screened over 8000 small molecules from a library of well-characterized and uncharacterized small molecules in three complementary assays. We evaluated the effect of each drug on (a) intracellular growth of *Brucella ovis* (b) axenic growth of *B. ovis*, and (c) cytotoxic effects on THP-1 macrophages. By conducting three independent screens, we were able to filter and select for small molecule candidates that were inhibitory to *Brucella* in the intracellular context and not directed to the bacterium axenically.

RESULTS

Ca²⁺ channel blockers, such as nifedipine, were among the top classes of small molecule candidates in our *B. ovis* screen, and our follow up studies revealed similar activity against the human and BSL-3 pathogen *Brucella abortus*.

DISCUSSION/CONCLUSIONS

Host Ca²⁺ homeostasis has been broadly investigated in other intracellular pathogens, however its importance for *Brucella* infection is relatively undefined. These preliminary data show that FDA approved Ca²⁺ modulators are an effective host-directed small molecule in vitro and more importantly show that Ca²⁺ homeostasis may play an essential role in *Brucella* pathogenesis in the macrophage.

Submitted: July 15, 2024 EDT. Accepted: July 31, 2024 EDT.

Published: August 30, 2024 EDT.

